Price$2.85-3.21 (-53.05%)
2026-07-152026-10-15
News · 26 weeks38-10%
2026-04-192026-10-11
Mix1990d
- Insider8(42%)
- SEC Filings5(26%)
- Other3(16%)
- Earnings2(11%)
- Leadership1(5%)
Latest news
25 items- SECSEC Form 6-K filed by Addex Therapeutics Ltd6-K - Addex Therapeutics Ltd. (0001574232) (Filer)
- PRAddex Spin-Out Neurosterix Completes Phase 1 Clinical Studies of NTX-253 for SchizophreniaAd Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, October 8, 2026 - Addex Therapeutics (NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that its spin-out company, Neurosterix, in which Addex holds a 20% equity interest, has completed its Phase 1 clinical studies evaluating NTX-253 and plans to advance NTX-253 into Phase 2 clinical development. NTX-253 is a positive allosteric modulator (PAM) of the muscarinic M4 receptor being developed for the treatment of schizophrenia. "Completing Phase 1 and the decision by Neurosterix to progress NTX-253
- SECSEC Form 6-K filed by Addex Therapeutics Ltd6-K - Addex Therapeutics Ltd. (0001574232) (Filer)
- PRAddex Therapeutics Announces Executive Management ChangesJean-Philippe Rocher Appointed Head of Pharmaceutical DevelopmentMikhail Kalinichev, Head of Translational Science, Steps Down Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, October 2, 2026 - Addex Therapeutics (SIX and NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced the appointment of Jean-Philippe Rocher as Head of Pharmaceutical Development and member of the Executive Management. Dr. Rocher has more than 30 years of experience in drug discovery and development within the pharmaceutical and biotech industry, including previous roles at Adde
- SECSEC Form 6-K filed by Addex Therapeutics Ltd6-K - Addex Therapeutics Ltd. (0001574232) (Filer)
- PRAddex Therapeutics Reports 2026 Half-Year Results and Provides Corporate UpdateAd Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 28, 2026 - Addex Therapeutics (SIX and NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its 2026 Half-Year and Second Quarter financial results and provided a corporate update. "The successful raising of USD 2.8 million during the last quarter enables us to continue advancing our in-house GABAB cough program towards clinical development. Coupled with recent regaining of all rights to the GABAB PAM program for substance use disorders from Indivior, due to R&D rationalization following its
- SECSEC Form 6-K filed by Addex Therapeutics Ltd6-K - Addex Therapeutics Ltd. (0001574232) (Filer)
- PRAddex Regains Rights to GABAB Positive Allosteric Modulator Portfolio from IndiviorAd Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 25, 2026 - Addex Therapeutics (NASDAQ:ADXN), a clinical-stage biopharmaceutical company developing novel small molecule allosteric modulators for neurological disorders, today announced that it has regained full global rights to all GABAB positive allosteric modulator (PAM) assets discovered under its research collaboration with Indivior UK Limited ("Indivior"). The return of the rights follows Indivior’s rationalization of its research and development activities and the announcement of the planned merger of Indivior’s parent company with Supernus Pharmaceuticals, Inc. "These GABAB PAM assets reflect years of world-c
- PRAddex Therapeutics to Report 2026 Half-Year Financial Results and Host Conference Call on September 28, 2026Geneva, Switzerland, September 24, 2026 - Addex Therapeutics (SIX and NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will report its 2026 Half-Year and Second Quarter financial results on September 28, 2026. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science, will provide a business update and review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) on September 28, 2026. Title: Addex Therapeutics Reports 2026 Half-Year and Second Qua
- INSIDERSEC Form 4 filed by PRINCIPAL ACCOUNTING OFFICER Teyssedou Lenaic Nathanael4 - Addex Therapeutics Ltd. (0001574232) (Issuer)
- INSIDERHEAD OF TRANSLATIONAL SCIENCE Kalinichev Mikhail returned 306,765 shares to the company and was granted 306,765 shares (SEC Form 4)4 - Addex Therapeutics Ltd. (0001574232) (Issuer)
- INSIDERDirector Nunn Jason Raleigh returned 219,561 shares to the company and was granted 219,561 shares (SEC Form 4)4 - Addex Therapeutics Ltd. (0001574232) (Issuer)
- INSIDERCHIEF MEDICAL OFFICER Mills Roger returned 392,837 shares to the company and was granted 392,837 shares (SEC Form 4)4 - Addex Therapeutics Ltd. (0001574232) (Issuer)
- INSIDERDirector Manke Isaac returned 219,561 shares to the company and was granted 219,561 shares (SEC Form 4)4 - Addex Therapeutics Ltd. (0001574232) (Issuer)
- INSIDERDirector Lawton Vincent Michael returned 2,507,487 shares to the company and was granted 2,507,487 shares (SEC Form 4)4 - Addex Therapeutics Ltd. (0001574232) (Issuer)
- INSIDERDirector Hill Raymond George returned 1,365,532 shares to the company and was granted 1,365,532 shares (SEC Form 4)4 - Addex Therapeutics Ltd. (0001574232) (Issuer)
- INSIDERCHIEF EXECUTIVE OFFICER Dyer Timothy Mark returned 16,413,787 shares to the company and was granted 16,413,787 shares (SEC Form 4)4 - Addex Therapeutics Ltd. (0001574232) (Issuer)
- SECSEC Form 6-K filed by Addex Therapeutics Ltd6-K - Addex Therapeutics Ltd. (0001574232) (Filer)
- PRADDEX raises USD 2.8 million through its ATM agreement and extends cash runway to the fourth quarter 2027Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, August 26, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it has raised gross proceeds of USD 2.8 million (CHF 2.2 million) through the sale of 437,869 ADSs representing 52,544,280 shares, through it’s At the Market (ATM) offering agreement with H.C. Wainwright & Co. Following the reported sale of these ADSs, Addex’s cash runway has been extended to the fourth quarter of 2027. The outstanding number of shares, excluding treasury shares, has increased to
- SECSEC Form 6-K filed by Addex Therapeutics Ltd6-K - Addex Therapeutics Ltd. (0001574232) (Filer)
- PRAddex Announces Publication of Research Highlighting Therapeutic Potential of mGlu7 Modulation in Regulating Sleep and WakefulnessAd Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 8, 2026 - Addex Therapeutics (NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced publication of new preclinical research demonstrating that ADX71743, a selective negative allosteric modulator (NAM) of metabotropic glutamate receptor 7 (mGlu7), significantly modulates sleep-wake regulation and stress-related neurochemistry in animal models. The data, published in the International Journal of Neuropsychopharmacology, expands the growing body of evidence supporting mGlu7 as an important mechanism
- SECSEC Form 6-K filed by Addex Therapeutics Ltd6-K - Addex Therapeutics Ltd. (0001574232) (Filer)
- PRAddex Shareholders Approve All Resolutions at Annual General MeetingAd Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 30, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced today that its shareholders approved, with a large majority, all proposals of the Board of Directors in its 2026 Annual General Meeting (AGM). The votes represented 29.35% of the company's outstanding capital. Addex shareholders approved the annual report, the consolidated financial statements and the annual financial statements for the year 2025, the appropriation of the results as well as the compensati
- SECSEC Form 6-K filed by Addex Therapeutics Ltd6-K - Addex Therapeutics Ltd. (0001574232) (Filer)
- PRAddex Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateAd Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 25, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its Q1 2026 financial results and provided a corporate update. "Our spin-out, Neurosterix, made great progress during the quarter and are on track to complete the Phase 1 study with NTX-253, an M4 positive allosteric modulator with potential in schizophrenia, in July," said Tim Dyer, CEO of Addex. "We look forward to seeing the data from the study when available later in the summer." Operating Highlights:
ADXN FAQ
6 questionsWhat does Addex Therapeutics Ltd do?
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals...Where does ADXN stock trade?
Addex Therapeutics Ltd (ADXN) is listed on NASDAQ.What sector and industry is ADXN in?
Addex Therapeutics Ltd operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about ADXN?
Addex Therapeutics Ltd has had 2 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy with a $3000.00 price target on 2024-07-31. Recent price targets range from $2100.00 to $3000.00.What companies are similar to ADXN?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare ADXN side-by-side with any of them on Quantisnow.How can I track ADXN on Quantisnow?
Quantisnow aggregates Addex Therapeutics Ltd's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ADXN to receive live email and push alerts on every new disclosure.